Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Omeros Corporation Stock Climbed Higher Today

By Cory Renauer - Mar 28, 2017 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for the company's clinical-stage candidate keeps pouring in.

What happened

Shares of Omeros Corporation (OMER -1.32%), a biotech developing a candidate for the treatment of rare blood disorders with limited treatment options, rose 12.3% at 3:50 p.m. EDT during Tuesday's session. The stock continued its climb after the company described a highly positive response from a girl who couldn't tolerate previous treatment from Alexion Pharmaceuticals' (ALXN) Soliris.

So what 

The lead candidate in clinical trials for Omeros, OMS721 is a unique drug that appears to prevent blood cell damage responsible for a range of rare disorders. On Monday, the company announced seven patients with atypical hemolytic uremic syndrome (aHUS) significantly benefited from treatment with the candidate. 

Finger pointing toward a rising chart.

Image source: Getty Images.

Today, the company presented a case study involving a single patient with an associated disease that couldn't tolerate Soliris treatment but responded well to OMS721. In fact, her disease is in remission and she's no longer dependent on dialysis or blood transfusions.

Now what

Soliris is currently the only effective treatment approved for the treatment of aHUS, and with an annual price tag of around $440,000, it's also one of the world's most expensive therapies. In 2016, Alexion recorded about $2.8 billion in Soliris sales, which might be a high-water mark if Omeros' OMS721 keeps producing results like these. A pivotal trial with aHUS patients is underway, and success would probably make it the second effective treatment for the rare condition.

Despite a 43% rise so far this year, Omeros' market cap is still a sprightly $628 million. While OMS721 alone appears to justify the company's price, it's already nearing sustainable positive cash flows with its commercial-stage drug, Omidria.

The pupil-dilating drug assists eye surgeons when removing cataracts and replacing lenses, common procedures performed millions of times each year in the U.S. alone. Although Omidria sales jumped 212% last year to $41.4 million, they've only scratched the surface. With one drug rocketing upward, and another quite possibly on the way, this tiny biotech is well worth your attention.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Omeros Corporation Stock Quote
Omeros Corporation
$2.61 (-1.32%) $0.04
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.